Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6409990 | CARDINAL HEALTH 414 | Macromolecular carrier for drug and diagnostic agent delivery |
May, 2025
(1 year, 14 days from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9439985 | CARDINAL HEALTH 414 | Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran |
Jan, 2029
(4 years from now) |
Lymphoseek Kit is owned by Cardinal Health 414.
Lymphoseek Kit contains Technetium Tc-99M Tilmanocept.
Lymphoseek Kit has a total of 2 drug patents out of which 0 drug patents have expired.
Lymphoseek Kit was authorised for market use on 13 March, 2013.
Lymphoseek Kit is available in injectable;injection dosage forms.
Drug patent challenges can be filed against Lymphoseek Kit from 13 March, 2017.
The generics of Lymphoseek Kit are possible to be released after 30 January, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | May 19, 2024 |
New Indication(I-687) | Jun 13, 2017 |
Orphan Drug Exclusivity(ODE) | Jun 13, 2021 |
Orphan Drug Exclusivity(ODE-67) | Jun 13, 2021 |
New Chemical Entity Exclusivity(NCE) | Mar 13, 2018 |
Drugs and Companies using
TECHNETIUM TC-99M TILMANOCEPT ingredient